Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Giulia Jole Burastero"'
Autor:
Claudia Alteri, Valeria Fox, Rossana Scutari, Giulia Jole Burastero, Sara Volpi, Matteo Faltoni, Vanessa Fini, Annarita Granaglia, Sara Esperti, Altea Gallerani, Valentino Costabile, Beatrice Fontana, Erica Franceschini, Marianna Meschiari, Andrea Campana, Stefania Bernardi, Alberto Villani, Paola Bernaschi, Cristina Russo, Giovanni Guaraldi, Cristina Mussini, Carlo Federico Perno
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-12 (2022)
A proof-of-concept study on the genomic evolution of SARS-CoV-2 during antiviral treatment reveals that Molnupiravir induces a higher in vivo intra-host variability compared to Paxlovid and drug-naive.
Externí odkaz:
https://doaj.org/article/d3d48f1280234ca4a779a922ba81a3d6
Autor:
Erica Franceschini, Giovanni Dolci, Antonella Santoro, Marianna Meschiari, Alice Riccò, Marianna Menozzi, Giulia Jole Burastero, Biagio Cuffari, Nicola De Maria, Lucia Serio, Emanuela Biagioni, Barbara Catellani, Stefano Di Sandro, Antonio Colecchia, Massimo Girardis, Fabrizio Di Benedetto, Cristina Mussini
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 254-256 (2023)
Objectives: Pneumocystis jirovecii pneumonia (PCP) incidence is increasing in people without HIV. Decompensated liver cirrhosis is not currently considered a risk factor for PCP. The aim of this paper is to describe a case series of patients with dec
Externí odkaz:
https://doaj.org/article/932d5a79b0004e8db2a0f9cc0f94cd6d
Autor:
Giovanni Dolci, Giulia Jole Burastero, Francesca Paglia, Adriana Cervo, Marianna Meschiari, Giovanni Guaraldi, Johanna Chester, Cristina Mussini, Erica Franceschini
Publikováno v:
Microorganisms, Vol 11, Iss 6, p 1606 (2023)
Invasive bacterial infections are a leading cause of morbidity and mortality after liver transplant (LT), especially during the first months after LT, and infections due to multi-drug-resistant organisms (MDRO) are increasing in this setting. Most of
Externí odkaz:
https://doaj.org/article/d30933ac41824da1852c81891505c108
Autor:
Giulia Jole Burastero, Gabriella Orlando, Antonella Santoro, Marianna Menozzi, Erica Franceschini, Andrea Bedini, Adriana Cervo, Matteo Faltoni, Erica Bacca, Emanuela Biagioni, Irene Coloretti, Gabriele Melegari, Jessica Maccieri, Stefano Busani, Elisabetta Bertellini, Massimo Girardis, Giulia Ferrarini, Laura Rofrano, Mario Sarti, Cristina Mussini, Marianna Meschiari
Publikováno v:
Antibiotics, Vol 11, Iss 8, p 1007 (2022)
Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a very huge global threat due to a higher incidence rate compared to non-COVID-19 patients and almost 50% of the 30-day mortality rate. Pseudomonas aeruginosa w
Externí odkaz:
https://doaj.org/article/3601da7add4e4d9487fa7c68f6a4d7b4
Autor:
Filippo Medioli, Erica Bacca, Matteo Faltoni, Giulia Jole Burastero, Sara Volpi, Marianna Menozzi, Gabriella Orlando, Andrea Bedini, Erica Franceschini, Cristina Mussini, Marianna Meschiari
Publikováno v:
Antibiotics, Vol 11, Iss 8, p 1015 (2022)
Background: Despite the global efforts to antagonize carbapenem-resistant Acinetobacter baumannii (CRAB) spreading, it remains an emerging threat with a related mortality exceeding 40% among critically ill patients. The purpose of this review is to p
Externí odkaz:
https://doaj.org/article/87fd99fff19d43d584ac8c80d5008466
Autor:
Claudia Alteri, Valeria Fox, Rossana Scutari, Giulia Jole Burastero, Sara Volpi, Matteo Faltoni, Vanessa Fini, Annarita Granaglia, Sara Esperti, Altea Gallerani, Valentino Costabile, Beatrice Fontana, Erica Franceschini, Marianna Meschiari, Andrea Campana, Stefania Bernardi, Alberto Villani, Paola Bernaschi, Cristina Russo, Giovanni Guaraldi, Cristina Mussini, Carlo Perno
Molnupiravir and Paxlovid are the only antivirals approved for COVID-19 treatment. Previous studies have evaluated their efficacy, tolerability, and viral clearance, but little is known about SARS-CoV-2 evolution under their pressure. Here the dynami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58671e4c46596cfd4c4437c462accf1b
https://doi.org/10.21203/rs.3.rs-2105569/v1
https://doi.org/10.21203/rs.3.rs-2105569/v1
Autor:
Carlo Salvarani, Marco Massari, Massimo Costantini, Domenico Franco Merlo, Gabriella Lucia Mariani, Pierluigi Viale, Stefano Nava, Giovanni Guaraldi, Giovanni Dolci, Luca Boni, Luisa Savoldi, Paolo Bruzzi, Caterina Turrà, Mariagrazia Catanoso, Anna Maria Marata, Chiara Barbieri, Annamaria Valcavi, Francesca Franzoni, Silvio Cavuto, Giorgio Mazzi, Romina Corsini, Fabio Trapani, Alessandro Bartoloni, Emanuela Barisione, Giulia Jole Burastero, Angelo Pan, Walter Inojosa, Raffaele Scala, Cecilia Burattini, Fabrizio Luppi, Mauro Codeluppi, Kamal Eldin Tarek, Giovanni Cenderello, Mario Salio, Giuseppe Foti, Roberto Dongilli, Gianluigi Bajocchi, Emanuele Alberto Negri, Giacomo Ciusa, Giacomo Fornaro, Ilaria Bassi, Lorenzo Zammarchi, Teresita Aloè, Nicola Facciolongo
RationalePulse glucocorticoid therapy is used in hyperinflammation related to coronavirus disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia.Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c8199487da1189b1a0650e4ccbf9fc
https://hdl.handle.net/11380/1277099
https://hdl.handle.net/11380/1277099